Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- MBRX
- Price
- 0.83
- Stock movement up
- +0.03 (3.65%)
- Company name
- Moleculin Biotech Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 2.49M
- Ent value
- 9.00M
- Price/Sales
- 3.06
- Price/Book
- 0.33
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -18.25%
- 1 year return
- -82.62%
- 3 year return
- -69.03%
- 5 year return
- -55.37%
- 10 year return
- -
Last updated: 2025-04-15
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
MBRX does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 3.06 |
| Price to Book | 0.33 |
| EV to Sales | 11.08 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 3.00M |
| EPS (TTM) | -8.12 |
| FCF per share (TTM) | -6.54 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 812.00K |
| Gross profit (TTM) | 308.00K |
| Operating income (TTM) | -28.92M |
| Net income (TTM) | -30.15M |
| EPS (TTM) | -8.12 |
| EPS (1y forward) | -5.28 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 37.93% |
| Operating margin (TTM) | -3561.08% |
| Profit margin (TTM) | -3713.05% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 9.40M |
| Net receivables | 0.00 |
| Total current assets | 11.61M |
| Goodwill | 0.00 |
| Intangible assets | 11.15M |
| Property, plant and equipment | 640.00K |
| Total assets | 23.39M |
| Accounts payable | 2.55M |
| Short/Current long term debt | 506.00K |
| Total current liabilities | 5.59M |
| Total liabilities | 15.91M |
| Shareholder's equity | 7.48M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -24.19M |
| Capital expenditures (TTM) | 175.00K |
| Free cash flow (TTM) | -24.28M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -403.13% |
| Return on Assets | -128.88% |
| Return on Invested Capital | -396.97% |
| Cash Return on Invested Capital | -319.68% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 0.84 |
| Daily high | 0.88 |
| Daily low | 0.80 |
| Daily Volume | 275K |
| All-time high | 801.00 |
| 1y analyst estimate | 18.00 |
| Beta | 1.86 |
| EPS (TTM) | -8.12 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 8 May 2025 |
Downside potential
Loading...
Downside potential data
| MBRX | S&P500 | |
| Current price drop from All-time high | -99.90% | -12.04% |
| Highest price drop | -99.95% | -56.47% |
| Date of highest drop | 12 Feb 2025 | 9 Mar 2009 |
| Avg drop from high | -88.11% | -11.07% |
| Avg time to new high | 1107 days | 12 days |
| Max time to new high | 2213 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
2.49M
Marketcap category
Small-cap
Description
Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs. The company is also developing WP1066, an immune/transcription modulator designed to inhibit phosphorylated signal transducer and activator of transcription and other oncogenic transcription factors targeting brain tumors, and pancreatic and other cancers. In addition, it develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat viruses, as well as cancer indications, including brain tumors, and pancreatic and other cancers. The company was incorporated in 2015 and is headquartered in Houston, Texas.
Employees
18
Website
Investor relations
-
SEC filings
CEO
Walter V. Klemp
Country
USA
City
Houston
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page